Cargando…

A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs

Background: Preclinical cell models are the mainstay in the early stages of drug development. We sought to explore the preclinical data that differentiated successful from failed therapeutic agents in lung cancer. Methods: One hundred thirty-four failed lung cancer drugs and twenty seven successful...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Elizabeth, Bogumil, David, Cortessis, Victoria, Yu, Sherrie, Nieva, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190806/ https://www.ncbi.nlm.nih.gov/pubmed/32391273 http://dx.doi.org/10.3389/fonc.2020.00591

Ejemplares similares

Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation
por: Geier, Brian, et al.
Publicado: (2015)

Lung cancer organoids: models for preclinical research and precision medicine
por: Liu, Yajing, et al.
Publicado: (2023)

Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2013)

Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models
por: Zheng, Qingfan, et al.
Publicado: (2022)

Preclinical Models of Malignant Mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2020)

Following the Preclinical Data: Leveraging the Abscopal Effect More Efficaciously
por: Ngwa, Wilfred, et al.
Publicado: (2017)

Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer
por: Rybinski, Brad, et al.
Publicado: (2020)

The Coming of Age of Preclinical Models of MDS
por: Liu, Wei, et al.
Publicado: (2022)

Preclinical modeling of lower-grade gliomas
por: Tang, Lilly W., et al.
Publicado: (2023)

Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

Editorial: Preclinical models and emerging technologies to study the effects of the tumor microenvironment on cancer heterogeneity and drug resistance
por: Adriani, Giulia, et al.
Publicado: (2023)

B cells as modulators of HPV+ oropharyngeal cancer in a preclinical model
por: Galán-Ortíz, Jorge R., et al.
Publicado: (2023)

The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
por: Blanquart, Christophe, et al.
Publicado: (2020)

Preclinical Models and Resources to Facilitate Basic Science Research on Malignant Mesothelioma – A Review
por: Johnson, Ben William, et al.
Publicado: (2021)

Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System
por: Singh, Mohini, et al.
Publicado: (2017)

Patient-Derived Xenografts Are a Reliable Preclinical Model for the Personalized Treatment of Epithelial Ovarian Cancer
por: Chen, Jiayu, et al.
Publicado: (2021)

Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma
por: Swayden, Mirna, et al.
Publicado: (2020)

Combining the DNA Repair Inhibitor Dbait With Radiotherapy for the Treatment of High Grade Glioma: Efficacy and Protein Biomarkers of Resistance in Preclinical Models
por: Biau, Julian, et al.
Publicado: (2019)

Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis
por: Zhong, Yu, et al.
Publicado: (2022)

Radiotherapy and Erlotinib Combined: Review of the Preclinical and Clinical Evidence
por: Mehta, Vivek K.
Publicado: (2012)

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance
por: Mahfoudhi, Emna, et al.
Publicado: (2022)

Evaluating the Treatment Efficacy of Nano-Drug in a Lung Cancer Model Using Advanced Functional Magnetic Resonance Imaging
por: Huang, Cuiqing, et al.
Publicado: (2020)

Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives
por: Raucher, Drazen, et al.
Publicado: (2018)

Tumor heterogeneity: preclinical models, emerging technologies, and future applications
por: Proietto, Marco, et al.
Publicado: (2023)

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
por: Timofeeva, Natalia, et al.
Publicado: (2023)

Efficacy of TTFields in high-grade gliomas: a protocol for systematic review and meta-analysis
por: Li, Xinlong, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
por: Yang, Fang, et al.
Publicado: (2022)

Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
por: Xia, Handai, et al.
Publicado: (2022)

A Systematic Analysis Identifies Key Regulators Involved in Cell Proliferation and Potential Drugs for the Treatment of Human Lung Adenocarcinoma
por: Wang, Kai, et al.
Publicado: (2021)

Efficacy and safety of mesenchymal stromal cells in preclinical models of acute lung injury: a systematic review protocol
por: Lalu, Manoj M, et al.
Publicado: (2014)

Efficacy of Mesenchymal Stromal Cell Therapy for Acute Lung Injury in Preclinical Animal Models: A Systematic Review
por: McIntyre, Lauralyn A., et al.
Publicado: (2016)

Evaluation of the potential of ultrasound-mediated drug delivery for the treatment of ovarian cancer through preclinical studies
por: Wang, Yi-Chao, et al.
Publicado: (2022)

Editorial: Targeting metabolism of cancer cells and host to overcome drug resistance: Preclinical and clinical studies
por: Wang, Lishun, et al.
Publicado: (2023)

The Efficacy and Safety of First-Line Chemotherapy in Patients With Non-small Cell Lung Cancer and Interstitial Lung Disease: A Systematic Review and Meta-Analysis
por: Wang, Yanning, et al.
Publicado: (2020)

Association of Brain Metastases With Immune Checkpoint Inhibitors Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis
por: Wang, Yanning, et al.
Publicado: (2021)

Cellular Therapies for the Treatment of Hematological Malignancies; Swine Are an Ideal Preclinical Model
por: Duran-Struuck, Raimon, et al.
Publicado: (2019)

Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers
por: Dreyfuss, Alexandra D., et al.
Publicado: (2022)

Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia
por: Branstrom, Arthur, et al.
Publicado: (2022)

Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials
por: Cheng, Jonathan H., et al.
Publicado: (2019)

Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response
por: Gu, Yihui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hj5unhhjc76uc0j71alm29o16h